NCT03405298

Brief Summary

The goal of this project is to reduce chronic benzodiazepine use through two approaches: direct patient education or direct patient education paired with additional support and encouragement from a behavioral health care manager.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
44

participants targeted

Target at P25-P50 for not_applicable

Timeline
Completed

Started Feb 2018

Shorter than P25 for not_applicable

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

January 12, 2018

Completed
11 days until next milestone

First Posted

Study publicly available on registry

January 23, 2018

Completed
16 days until next milestone

Study Start

First participant enrolled

February 8, 2018

Completed
7 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

September 20, 2018

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

September 20, 2018

Completed
Last Updated

October 11, 2018

Status Verified

October 1, 2018

Enrollment Period

7 months

First QC Date

January 12, 2018

Last Update Submit

October 10, 2018

Conditions

Outcome Measures

Primary Outcomes (2)

  • Change in avg. daily dose of benzodiazepine prescribed in lorazepam-equivalent mg

    Compare the average daily dose during month 3 to the baseline average daily dose

    3 months

  • Change in avg. daily dose of benzodiazepine prescribed in lorazepam-equivalent mg

    Compare the average daily dose during month 6 to the baseline average daily dose

    6 months

Secondary Outcomes (8)

  • Patient Health Questionnaire (PHQ-8)

    3 months

  • Generalized Anxiety Disorder 7-Item Scale (GAD-7)

    3 months

  • Insomnia Severity Index (ISI)

    3 months

  • Alcohol Use Disorders Identification Test (AUDIT-C)

    3 months

  • PHQ-8

    6 months

  • +3 more secondary outcomes

Study Arms (2)

Educational Material with Collaborative Care available

ACTIVE COMPARATOR

In addition to the material described below, these patients are seen in clinics with behavioral health collaborative care (BHCC), which includes a care manager in the primary care provider's office along with a consulting psychiatrist. If a patient receives the brochure and would like to taper their benzodiazepine, their provider can refer them to the BHCC care manager who can provide education and anxiety and insomnia self-management strategies, while the BHCC psychiatrist will make recommendations regarding the medication taper back to the primary care provider.

Behavioral: Educational MaterialBehavioral: Supplemental Collaborative Care

Educational Material Only

ACTIVE COMPARATOR

Patients will receive an 8-page educational brochure that presents information about potential harms of these medications and a vignette about a patient that successfully stopped. It does NOT suggest patients to stop on their own, but rather suggests they speak with their provider.

Behavioral: Educational Material

Interventions

Educational material is in the form of a brochure

Educational Material OnlyEducational Material with Collaborative Care available

Supplemental care management consist of meeting with a behavioral health care manager over five sessions in-person or via phone call; the care manager will review patient information with the consulting psychiatrist, who can then make recommendations back to the primary care provider

Educational Material with Collaborative Care available

Eligibility Criteria

Age50 Years+
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • With a prescription BZD supply covering ≥20% of days in the preceding 12 months ("chronic").

You may not qualify if:

  • Patients with BZD supply \<20% days in past 12 months
  • Patients with ICD-10 codes for dementia (derived from encounter diagnosis codes)
  • long-term care residents (ICD-10 codes Z59.3 and Y92.199)

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Department of Psychiatry, University of Michigan

Ann Arbor, Michigan, 48109, United States

Location

Study Officials

  • Donovan Maust, MS, MD

    University of Michigan

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
NON RANDOMIZED
Masking
NONE
Purpose
SUPPORTIVE CARE
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Professor of Psychiatry

Study Record Dates

First Submitted

January 12, 2018

First Posted

January 23, 2018

Study Start

February 8, 2018

Primary Completion

September 20, 2018

Study Completion

September 20, 2018

Last Updated

October 11, 2018

Record last verified: 2018-10

Data Sharing

IPD Sharing
Will not share

Locations